vtioВестник трансплантологии и искусственных органовRussian Journal of Transplantology and Artificial Organs1995-1191Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation10.15825/1995-1191-2020-2-165-170vtio-1198Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSКонтроль концентрации такролимуса в кровиMonitoring tacrolimus whole blood concentrationsГичкунО. Е.GichkunO. E.

Гичкун Ольга Евгеньевна

Адрес: 123182, Москва, ул. Щукинская, д. 1. Тел. (499) 190-38-77.

Olga Gichkun

Address: 1, Shchukinskaya str., Moscow, 123182. Tel. (499) 190-38-77.

Gichkunoe@yandex.ruФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава России; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский университет)РоссияShumakov National Medical Research Center of Transplantology and Artificial Organs; Sechenov UniversityRussian Federation202012072020222165170Copyright © Гичкун О.Е., 20202020Гичкун О.Е.Gichkun O.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.transpl.ru/vtio/article/view/1198

Такролимус (TAС) – базовый препарат для большинства схем иммуносупрессивной терапии, с узким терапевтическим окном: недостаточная доза препарата может привести к отторжению органов и тканей, избыточная – к увеличению риска инфекций, токсичности, злокачественным новообразованиям у реципиентов трансплантированных органов. ТАС относится к препаратам группы ингибиторов кальциневрина, подавляющих функцию Т-лимфоцитов. Прием ТАС сопряжен с регулярным клиническим наблюдением реципиентов и лабораторным контролем концентрации препарата в крови для обеспечения правильной дозировки лекарства и ограничения потенциального риска вредных побочных эффектов. В обзоре представлены данные о некоторых клинических, генетических факторах, влияющих на биодоступность и концентрацию ТАС в крови, а также методические аспекты ее лабораторного контроля.

Tacrolimus (TAC) is the primary drug for most immunosuppressive therapy regimens. It has a narrow therapeutic index, meaning that insufficient dose can lead to graft and tissue rejection, while overdose can lead to increased risk of infections, toxicity, and cancerous tumors in organ transplant recipients. TAC belongs to a group of calcineurin inhibitors inhibiting T-cell activation. The use of TAC requires regular clinical observation of recipients and laboratory monitoring of the drug concentrations in the blood. This is to ensure correct dosage of the drug and to limit the potential risk of harmful side effects. The review presents data on some clinical, genetic factors affecting the bioavailability and concentration of TAC in the blood. We also present data on the methodological aspects of TAC laboratory control.

такролимусполиморфизм гена P450протоколы назначениялекарственный мониторингтрансплантация органовtacrolimusP450 gene polymorphismprescription protocolsdrug monitoringorgan transplantationИсследование профинансировано грантом Президента Российской Федерации НШ-2598.2020.7 для государственной поддержки ведущих научных школ РФ.ReferencesИммуносупрессия при трансплантации солидных органов / Под ред. С.В. Готье. М.–Тверь: Триада, 2011. 472 с.: ил.Immunosupressiya pri transplantatsii solidnykh organov / Pod red. S.V. Gautier. M.–Tver’: Triada, 2011. 472 s.: il.Bowman LJ, Brennan DC. The role of tacrolimus in renal transplantation. Expert Opin Pharmacother. 2008; 9 (4): 635–643.Bowman LJ, Brennan DC. The role of tacrolimus in renal transplantation. Expert Opin Pharmacother. 2008; 9 (4): 635–643.Готье СВ, Шевченко АО, Попцов ВН. Пациент с трансплантированным сердцем. Руководство для врачей по ведению пациентов, перенесших трансплантацию сердца. М.–Тверь: Триада, 2014. 144 с.Gautier SV, Shevchenko AO, Popcov VN. Pacient s transplantirovannym serdcem. Rukovodstvo dlja vrachej po vedeniju pacientov, perenesshih transplantaciju serdca. M.–Tver’: Triada, 2014. 144.Gao L, Liu J, Zhang Y et al. Low incidence of acute graft-versus-host disease with short-term tacrolimus in haploidentical hematopoietic stem cell transplantation. Leuk Res. 2017; 57: 27–36.Gao L, Liu J, Zhang Y et al. Low incidence of acute graft-versus-host disease with short-term tacrolimus in haploidentical hematopoietic stem cell transplantation. Leuk Res. 2017; 57: 27–36.Maguire O, Tornatore KM, O’Loughlin KL et al. Nuclear translocation of nuclear factor of activated T cells (NFAT) as a quantitative pharmacodynamic parameter for tacrolimus. Cytometry A. 2013; 83: 1096–1104.Maguire O, Tornatore KM, O’Loughlin KL et al. Nuclear translocation of nuclear factor of activated T cells (NFAT) as a quantitative pharmacodynamic parameter for tacrolimus. Cytometry A. 2013; 83: 1096–1104.Nassereddine S, Rafei H, Elbahesh E, Tabbara I. Acute graft versus host disease: a comprehensive review. Anticancer Res. 2017; 37 (4): 1547–1555.Nassereddine S, Rafei H, Elbahesh E, Tabbara I. Acute graft versus host disease: a comprehensive review. Anticancer Res. 2017; 37 (4): 1547–1555.Yu M, Liu M, Zhang W, Ming Y. Pharmacokinetics, рharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation. Curr Drug Metab. 2018; 19 (6): 513–522.Yu M, Liu M, Zhang W, Ming Y. Pharmacokinetics, рharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation. Curr Drug Metab. 2018; 19 (6): 513–522.Vanhove T, Annaert P, Kuypers DRJ. Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. Drug Metab Rev. 2016; 48 (1): 88–112.Vanhove T, Annaert P, Kuypers DRJ. Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. Drug Metab Rev. 2016; 48 (1): 88–112.Tang JT et al. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations. Expert Opin Drug Metab Toxicol. 2016; 12 (5): 555–565.Tang JT et al. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations. Expert Opin Drug Metab Toxicol. 2016; 12 (5): 555–565.Shuker N et al. A randomized controlled trial comparing the efficacy ofCyp3a5 genotype-based with body-weight-based tacrolimus dosing after living donor kidney transplantation. Am J Transplant. 2016; 16 (7): 2085–2096.Shuker N et al. A randomized controlled trial comparing the efficacy ofCyp3a5 genotype-based with body-weight-based tacrolimus dosing after living donor kidney transplantation. Am J Transplant. 2016; 16 (7): 2085–2096.Birdwell KA et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 Genotype and tacrolimus dosing. Clin Pharmacol Ther. 98 X. Zhang et al. Biomedicine & Pharmacotherapy. 2018; 102: 107–114. 2015; 1: 19–24.Birdwell KA et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 Genotype and tacrolimus dosing. Clin Pharmacol Ther. 98 X. Zhang et al. Biomedicine & Pharmacotherapy. 2018; 102: 107–114. 2015; 1: 19–24.Цирульникова ОМ,ЛурьеЮЭ, Цирульникова ИЕ. Особенности иммуносупрессивной терапии у детей. Иммуносупрессивная терапия у детей при трансплантации печени. Иммуносупрессия при трансплантации солидных органов. М.–Тверь: Триада; 2011: 273–337.Tsirulnikova OM, Lurie YuE, Tsirulnikova IE. Features of immunosupressive therapy in children. Immunosupressive therapy in children at liver transplantation. Immunosupression at solid organ transplantation. M.–Tver: Triada; 2011: 273–337. [In Russian].Agarwal A, Pescovitz MD. Immunosupression in pediatric solid organ transplantation. Semin Pediatr Surg. 2006 Aug; 15 (3): 142–152.Agarwal A, Pescovitz MD. Immunosupression in pediatric solid organ transplantation. Semin Pediatr Surg. 2006 Aug; 15 (3): 142–152.Turmelle YP, Nadler ML, Anderson CD et al. Towards minimizing immunosuppression in pediatric liver transplant recipients. Pediatr Transplantation. 2009; 13: 553–559.Turmelle YP, Nadler ML, Anderson CD et al. Towards minimizing immunosuppression in pediatric liver transplant recipients. Pediatr Transplantation. 2009; 13: 553–559.Hao GX, Song LL, Zhang DF et al. Off-label use of tacrolimus in children with glomerular disease: Effectiveness, safety and pharmacokinetics. Br J Clin Pharmacol. 2020 Feb; 86 (2): 274–284. doi: 10.1111/bcp.14174. Epub 2020 Jan 14.Hao GX, Song LL, Zhang DF et al. Off-label use of tacrolimus in children with glomerular disease: Effectiveness, safety and pharmacokinetics. Br J Clin Pharmacol. 2020 Feb; 86 (2): 274–284. doi: 10.1111/bcp.14174. Epub 2020 Jan 14.Fuchs A, Csajka C, Thoma Y, Buclin T, Widmer N. Benchmarking therapeutic drug monitoring software: a review of available computer tools. Clin Pharmacokinet. 2013; 52: 9–22. http://dx.doi.org/10.1007/s40262-012-0020-y.Fuchs A, Csajka C, Thoma Y, Buclin T, Widmer N. Benchmarking therapeutic drug monitoring software: a review of available computer tools. Clin Pharmacokinet. 2013; 52: 9–22. http://dx.doi.org/10.1007/s40262-012-0020-y.Burton ME, Brater DC, Chen PS, Day RB, Huber PJ, Vasko MR. A Bayesian feedback method of aminoglycoside dosing. Clin Pharmacol Ther. 1985; 37: 349–357.Burton ME, Brater DC, Chen PS, Day RB, Huber PJ, Vasko MR. A Bayesian feedback method of aminoglycoside dosing. Clin Pharmacol Ther. 1985; 37: 349–357.Woillard J-B, de Winter BCM, Kamar N, Marquet P, Rostaing L, Rousseau A. Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations – twice daily Prograf and once daily Advagraf. Br J Clin Pharmacol. 2011; 71: 391–402, http://dx.doi.org/10.1111/j.1365-2125.2010.03837.x.Woillard J-B, de Winter BCM, Kamar N, Marquet P, Rostaing L, Rousseau A. Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations – twice daily Prograf and once daily Advagraf. Br J Clin Pharmacol. 2011; 71: 391–402, http://dx.doi.org/10.1111/j.1365-2125.2010.03837.x.Gounden V, Soldin SJ. Tacrolimus measurement: building a better immunoassay. Clin Chem. 2014; 60 (4): 575–576.Gounden V, Soldin SJ. Tacrolimus measurement: building a better immunoassay. Clin Chem. 2014; 60 (4): 575–576.McShane AJ, Bunch DR, Wang S. Therapeutic drug monitoring of immunosuppressants by liquid chromatography – mass spectrometry. Clin Chim Acta. 2016; 454: 1–5.McShane AJ, Bunch DR, Wang S. Therapeutic drug monitoring of immunosuppressants by liquid chromatography – mass spectrometry. Clin Chim Acta. 2016; 454: 1–5.Bargnoux AS, Sutra T, Badiou S et al. Evaluation of the new Siemens tacrolimus assay on the Dimension EXL integrated chemistry system analyzer: comparison with an ultra-performance liquid chromatography-tandem mass spectrometry method. Ther Drug Monit. 2016; 38 (6): 808–812.Bargnoux AS, Sutra T, Badiou S et al. Evaluation of the new Siemens tacrolimus assay on the Dimension EXL integrated chemistry system analyzer: comparison with an ultra-performance liquid chromatography-tandem mass spectrometry method. Ther Drug Monit. 2016; 38 (6): 808–812.Polledri E, Mercadante R, Ferraris Fusarini C, Maiavacca R, Fustinoni S. Immunosuppressive drugs in whole blood: validation of a commercially available liquid chromatography/tandem mass spectrometry kit andcomparison with immunochemical assays. Rapid Commun Mass Spectrom. 2017; 31 (13): 1111–1120.Polledri E, Mercadante R, Ferraris Fusarini C, Maiavacca R, Fustinoni S. Immunosuppressive drugs in whole blood: validation of a commercially available liquid chromatography/tandem mass spectrometry kit andcomparison with immunochemical assays. Rapid Commun Mass Spectrom. 2017; 31 (13): 1111–1120.Koster RA, Veenhof H, Botma R et al. Dried blood spot validation of five immunosuppressants, without hematocrit correction, on two LC-MS/MS systems. Bioanalysis. 2017; 9 (7): 553–563.Koster RA, Veenhof H, Botma R et al. Dried blood spot validation of five immunosuppressants, without hematocrit correction, on two LC-MS/MS systems. Bioanalysis. 2017; 9 (7): 553–563.Koster RA, Alffenaar JW, Greijdanus B, Uges DR. Fast LC-MS/MS analysis of tacrolimus, sirolimus, everolimus and cyclosporine A in dried blood spots and the influence of the hematocrit and immunosuppressant concentration on recovery. Talanta. 2013; 115: 47–54.Koster RA, Alffenaar JW, Greijdanus B, Uges DR. Fast LC-MS/MS analysis of tacrolimus, sirolimus, everolimus and cyclosporine A in dried blood spots and the influence of the hematocrit and immunosuppressant concentration on recovery. Talanta. 2013; 115: 47–54.McShane AJ, Bunch DR, Wang S. Therapeutic drug monitoring of immunosuppressants by liquid chromatography – mass spectrometry. Clin Chim Acta. 2016; 454: 1–5.McShane AJ, Bunch DR, Wang S. Therapeutic drug monitoring of immunosuppressants by liquid chromatography – mass spectrometry. Clin Chim Acta. 2016; 454: 1–5.Шевченко АО, Никитина ЕА, Колоскова НН, Шевченко ОП, Готье СВ. Контролируемая артериальная гипертензия и выживаемость без нежелательных событий у реципиентов сердца. Кардиоваскулярная терапия и профилактика. 2018; 17 (4): 4–11.Shevchenko AO, Nikitina EA, Koloskova NN, Shevchenko OP, Gautier SV. Kontroliruemaja arterial’naja gipertenzija i vyzhivaemost’ bez nezhelatel’nyh sobytij u recipientov serdca. Kardiovaskuljarnaja terapija i profilaktika. 2018; 17 (4): 4–11. [In Russ, English abstract].

The authors declare that there are no conflicts of interest present.